{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:05:56Z","timestamp":1789502756760,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13714-9","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T22:53:11Z","timestamp":1754520791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab"],"prefix":"10.1038","volume":"15","author":[{"given":"Toshihiko","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinatsu","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyo","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogen","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Nakasya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Tsuduki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiji","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Sasamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"3","key":"13714_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3), 209\u2013249 (2021).","journal-title":"CA Cancer J Clin."},{"key":"13714_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"issue":"10389","key":"13714_CR3","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet. 401(10389), 1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7 (2023).","journal-title":"Lancet."},{"key":"13714_CR4","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141. https:\/\/doi.org\/10.1038\/s41591-023-02465-7 (2023).","journal-title":"Nat. Med."},{"issue":"10294","key":"13714_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab pluschemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction, and oesophageal adenocarcinoma(CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398(10294), 27\u201340 (2021).","journal-title":"Lancet"},{"issue":"11","key":"13714_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24(11), 1181\u20131195. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6 (2023).","journal-title":"Lancet Oncol."},{"issue":"35","key":"13714_CR7","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka, S. et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 31(35), 4438\u20134444 (2013).","journal-title":"J Clin Oncol."},{"key":"13714_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","volume":"2","author":"K Shitara","year":"2017","unstructured":"Shitara, K. et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label,randomized, non-inferiority, phase 3 trial. Lancet Gastroenterol. Hepatol. 2, 277\u2013287 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"13714_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin, J. L. et al. Phase I pharmacologic and biologic study of ramucirumab (IMC1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28, 780\u2013787 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"13714_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","volume":"23","author":"T Eguchi Nakajima","year":"2020","unstructured":"Eguchi Nakajima, T. et al. Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G). Gastric Cancer 23(4), 677\u2013688 (2020).","journal-title":"Gastric Cancer"},{"issue":"4","key":"13714_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s10147-022-02114-y","volume":"27","author":"A Nakasya","year":"2022","unstructured":"Nakasya, A. et al. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: A multicenter, propensity score-matched analysis (CROSS SELL study). Int. J. Clin. Oncol. 27(4), 684\u2013694 (2022).","journal-title":"Int. J. Clin. Oncol."},{"issue":"12","key":"13714_CR12","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","volume":"22","author":"I Chau","year":"2004","unstructured":"Chau, I. et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2014pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J. Clin. Oncol. 22(12), 2395\u20132403 (2004).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"13714_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10120-017-0702-0","volume":"20","author":"D Takahari","year":"2017","unstructured":"Takahari, D. et al. Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials. Gastric Cancer 20(5), 757\u2013763 (2017).","journal-title":"Gastric Cancer"},{"issue":"4","key":"13714_CR14","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s13277-013-1426-3","volume":"35","author":"N Fang","year":"2014","unstructured":"Fang, N. et al. Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites. Tumor Biol. 35(4), 3261\u20133268 (2014).","journal-title":"Tumor Biol."},{"issue":"6","key":"13714_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/ags3.12386","volume":"4","author":"M Honda","year":"2020","unstructured":"Honda, M. et al. An ascites grading system for predicting the prognosis of gastric cancer with peritoneum dissemination. Ann. Gastroenterol Surg. 4(6), 660\u2013666 (2020).","journal-title":"Ann. Gastroenterol Surg."},{"issue":"1","key":"13714_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10120-011-0056-y","volume":"15","author":"S Iwasa","year":"2012","unstructured":"Iwasa, S. et al. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. Gastric Cancer 15(1), 21\u201326 (2012).","journal-title":"Gastric Cancer"},{"issue":"1","key":"13714_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1186\/s12885-020-07614-6","volume":"20","author":"M Okunaka","year":"2020","unstructured":"Okunaka, M. et al. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. BMC Cancer 20(1), 1111 (2020).","journal-title":"BMC Cancer"},{"key":"13714_CR18","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (rainbow): A double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u20131235 (2014).","journal-title":"Lancet Oncol."},{"key":"13714_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejca.2017.11.032","volume":"91","author":"H Bando","year":"2018","unstructured":"Bando, H. et al. A phase II study of nab-paclitaxel in combination with ramucirmub in patients with previously treated advanced gastric cancer. Eur. J. Cancer. 91, 86\u201391 (2018).","journal-title":"Eur. J. Cancer."},{"key":"13714_CR20","doi-asserted-by":"crossref","unstructured":"Hirata K, Hamamoto Y, Shoji H, et al. A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G\/P-SELECT). J Clin Oncol 2022;40:suppl #280","DOI":"10.1200\/JCO.2022.40.4_suppl.280"},{"key":"13714_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/1759-7714.12998","volume":"10","author":"A Shiono","year":"2019","unstructured":"Shiono, A. et al. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. Thorac Cancer 10, 775\u2013781 (2019).","journal-title":"Thorac Cancer"},{"key":"13714_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","volume":"13","author":"SE Park","year":"2018","unstructured":"Park, S. E. et al. Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol 13, 106\u2013111 (2018).","journal-title":"J Thorac Oncol"},{"key":"13714_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","volume":"112","author":"G Schvartsman","year":"2017","unstructured":"Schvartsman, G. et al. Response rates to singleagent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112, 90\u201395 (2017).","journal-title":"Lung Cancer"},{"key":"13714_CR24","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.21873\/anticanres.13688","volume":"39","author":"D Harada","year":"2019","unstructured":"Harada, D. et al. Previous immune checkpoint inhibitor treatment to increase the efficacy of docetaxel and ramucirumab combination chemotherapy. Anticancer Res 39, 4987\u20134993 (2019).","journal-title":"Anticancer Res"},{"key":"13714_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck, M. et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 37, 537\u2013546 (2019).","journal-title":"J Clin Oncol."},{"key":"13714_CR26","doi-asserted-by":"publisher","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa, A. et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3, e59125. https:\/\/doi.org\/10.1172\/jci.insight.59125 (2018).","journal-title":"JCI Insight"},{"key":"13714_CR27","doi-asserted-by":"publisher","first-page":"v420","DOI":"10.1093\/annonc\/mdx376.050","volume":"28","author":"JC Sachdev","year":"2017","unstructured":"Sachdev, J. C. et al. Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti\u2013PD\u20131 monoclonal antibody, in patients (PTS) with advanced solid tumors. Ann. Oncol. 28, v420\u2013v427 (2017).","journal-title":"Ann. Oncol."},{"key":"13714_CR28","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1016\/S0618-8278(19)31207-1","volume":"70","author":"C-W Chen","year":"2019","unstructured":"Chen, C.-W. et al. FRI-471-Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization. J. Hepatol. 70, e605\u2013e606 (2019).","journal-title":"J. Hepatol."},{"key":"13714_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato, Y. et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE 14, e0212513 (2019).","journal-title":"PLoS ONE"},{"key":"13714_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000775","volume":"4","author":"A Sasaki","year":"2020","unstructured":"Sasaki, A. et al. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open 4, e000775 (2020).","journal-title":"ESMO Open"},{"issue":"6","key":"13714_CR31","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.21037\/jgo-23-598","volume":"14","author":"Y Jeon","year":"2023","unstructured":"Jeon, Y. et al. The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer. J. Gastrointest Oncol. 14(6), 2346\u20132353 (2023).","journal-title":"J. Gastrointest Oncol."},{"issue":"23","key":"13714_CR32","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2217\/fon-2019-0243","volume":"15","author":"F De Vita","year":"2019","unstructured":"De Vita, F. et al. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: Subgroup analysis from RAINBOW study. Future Oncol. 15(23), 2723\u20132731 (2019).","journal-title":"Future Oncol."},{"key":"13714_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12885-018-4057-7","volume":"18","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto, H. et al. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer 18, 120. https:\/\/doi.org\/10.1186\/s12885-018-4057-7 (2018).","journal-title":"BMC Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13714-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:13:16Z","timestamp":1757369596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13714-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13714"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13714-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Toshihiko Matsumoto received research funding from Ono Pharmaceutical Co, Ltd and Sanofi Co, Ltd; honoraria from Bayer Co, Ltd, Bristol-Myers Squibb Co, Ltd, Chugai Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Eli Lilly Japan Co, Ltd, Merck Bio Pharma Co, Ltd, MSD Co, Ltd, Ono Pharmaceutical Co, Ltd, Sanofi Co, Ltd, Taiho Pharmaceutical Co, Ltd, Takeda Co, Ltd, Teijin Pharmaceutical Co, Ltd and Yakult Honsha Co, Ltd. Hironaga Satake received lecture fees from Chugai, Takeda, and Merck Biopharma. All other authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"28841"}}